Minimal clinically important differences for measures of treatment efficacy in Stevens-Johnson syndrome and toxic epidermal necrolysis - 10/11/18

Whan B. Kim, MD ^a, Brandon Worley, MD, MSc ^a, James Holmes, MD ^b, Elizabeth J. Phillips, MD, FRCPC, FACP ^{c, d}, Jennifer Beecker, MD, CCFP(EM), FRCPC, DABD ^{a, ⁎}

^a Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, Canada 

^b Wake Forest University School of Medicine, Ottawa, Canada 

^c Department of Medicine, Vanderbilt University Medical Center, Ottawa, Canada 

^d Institute for Immunology & Infectious Diseases, Murdoch University, Ottawa, Canada 

^∗Reprint requests: Jennifer Beecker, MD, CCFP(EM), FRCPC, DABD, Division of Dermatology, Department of Medicine, University of Ottawa, The Ottawa Hospital Civic Campus, 4th Floor, 737 Parkdale Ave, Ottawa, Ontario K1Y-1J8, CanadaDivision of DermatologyDepartment of MedicineUniversity of OttawaThe Ottawa Hospital Civic Campus, 4th Floor, 737 Parkdale AveOttawaOntarioK1Y-1J8Canada